Pharmacodynamics of cefepime in patients with Gram-negative infections.
about
The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemIntegration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.β-lactam antibiotic concentrations during continuous renal replacement therapy.High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery.Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosaIndividualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function.Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapyPopulation pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care unitsImpact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infectionsSetting and revising antibacterial susceptibility breakpoints.Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignanciesPharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?Short versus long infusion of meropenem in very-low-birth-weight neonatesOptimizing antibiotic treatment for ventilator-associated pneumonia.Pharmacodynamics of antimicrobials: treatment optimisation.Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.Treatment of Pseudomonas aeruginosa infection in critically ill patients.Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous HemofiltrationPharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections.Pharmacokinetics and pharmacodynamics of antimicrobials.Ideal microbiological and pharmacological characteristics of a quality antimicrobial agent: comparing original and generic molecules.Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignanciesCefepime: a reappraisal in an era of increasing antimicrobial resistance.Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.Antimicrobial susceptibility testing: a primer for clinicians.Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.Patient Variables Associated with Nafcillin Plasma Concentrations and Toxicity.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?
P2860
Q28289744-88C20E5E-3BA1-4708-8F72-F16F8F753244Q30775587-F9489F57-EB30-4305-8FC7-2D0DB2024238Q33555775-B1E6CEAB-76B1-4760-A103-8B2956A350C1Q33676227-8D59A763-6508-4EF5-B2E6-48D0CB991E0AQ33821438-1880F719-82BA-49D0-94C0-D78DBEB833F9Q34057385-815ACB9E-6D0A-4285-AED3-B19186532E7CQ34153182-079E2440-9FBF-458F-BD68-1A5ACD9B1E64Q34228382-F25B4506-7F8A-49C1-8AAB-6A4CC1157611Q34274190-779DDC57-78E3-41D5-803A-C42543D953A9Q34307105-4D24C2DC-87AB-423A-B285-12C2BA9B83F4Q34894900-74334394-2D0D-4D3E-AC64-D227DA141A35Q35013708-755C7887-26CE-4DD1-9134-8FFB7D5B7A91Q35558292-57880805-E849-4E02-8DF3-B59C665F7E1BQ35607715-0B81C0A5-97AC-4C75-8678-BEEBC5724D30Q35746258-5E1AAC32-C97F-471C-AFFC-E1B7D75A521DQ35759054-02F98E5B-2F29-49B5-9114-E7FF392F47F0Q35913176-C5B22B4B-7E27-4693-ACD3-EA8CEADF1715Q35960873-1DCBF91F-0BEC-4A1E-9312-74D0174E386CQ36083619-C7D39FA7-CED6-41AF-96BF-F9D49EEEF37EQ36158212-73215C2E-AE9A-408D-82EA-A51176C23060Q36172523-B82C1BA5-8B7B-4545-A436-3C2797536892Q36390901-5788B919-B270-44E7-B995-C44095862BD6Q36544935-7932368D-5550-4E24-B32C-DAC41B345C22Q36582692-820D1805-2EE6-44C2-9252-0248FD4785D5Q36607415-C738E4FD-1482-42C8-97E1-F91EE1E0D3C2Q36644705-AA7F2D84-B41F-4ABA-BF60-163388DA4ACBQ36771321-73179BDE-87F8-4D83-B407-FDA4233679C4Q36854798-284D5D8C-0F1B-4993-9D75-09CEBD604C52Q37071315-FE156160-C9C9-4E7F-B3E1-AE596F61E000Q37072039-1628F0A5-088E-4257-8EBA-53D1E5C89A47Q37079350-DE925746-A54A-4FC8-853F-CD2A266179D7Q37335859-91CEC2E6-FCA5-4640-A536-61EC1E3B5BFFQ37621552-0A48FB98-98CF-440E-AEE0-446CDA58EB6CQ37625193-3C8951FB-7AA4-45A3-A8DE-DC048DF1ACE0Q38004063-35B4F293-9A1D-4A9D-8361-DCC9B9B1D10CQ38117578-3E31437A-17D9-4116-866F-BA574D5F00DBQ38165138-329335D4-FE12-4349-9894-28CD23C5A640Q38313276-7DCA7B56-76C5-41DF-8258-F9CC5F28B365Q38916860-6542E37C-E42E-4EDC-9344-BC14C3D53A89Q39344408-31901664-17E9-411B-A3F8-E72CC221837B
P2860
Pharmacodynamics of cefepime in patients with Gram-negative infections.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Pharmacodynamics of cefepime in patients with Gram-negative infections.
@en
Pharmacodynamics of cefepime in patients with Gram-negative infections.
@nl
type
label
Pharmacodynamics of cefepime in patients with Gram-negative infections.
@en
Pharmacodynamics of cefepime in patients with Gram-negative infections.
@nl
prefLabel
Pharmacodynamics of cefepime in patients with Gram-negative infections.
@en
Pharmacodynamics of cefepime in patients with Gram-negative infections.
@nl
P2093
P356
P1476
Pharmacodynamics of cefepime in patients with Gram-negative infections.
@en
P2093
George L Drusano
Michael J Rybak
Peggy S McKinnon
Ronda L Akins
Vincent H Tam
P304
P356
10.1093/JAC/DKF130
P407
P577
2002-09-01T00:00:00Z